Morgan Stanley Enters Indian Healthcare Space with  Acquisition of Gurugram-Based ClearMedi Healthcare for INR 285 Cr

Morgan Stanley, a global financial powerhouse, has acquired a majority stake in Gurugram-based ClearMedi Healthcare, marking its debut in Indian healthcare. 

ClearMedi runs a chain of oncology hospitals and radiation therapy centres. With this acquisition, the company is preparing to strengthen its position in the healthcare market under Commander Navneet Bali.

Commander Bali, with a distinguished 25-year career in the Indian Navy and successful leadership roles at Narayana Health and IOSPL, brings a wealth of experience to lead ClearMedi Healthcare.

As part of Morgan Stanley's acquisition of ClearMedi Healthcare, the holding company will receive a controlling stake valued at approximately $35 million (INR 285 Cr). 

The deal involved the purchase of a majority stake from Italy's KOS Group and a fresh equity injection into the company.

Morgan Stanley's backing injects substantial momentum into ClearMedi's market presence. Leveraging Morgan Stanley's extensive financial expertise and resources, ClearMedi strategically positions itself to expand its reach, invest in innovative technologies, and uphold its commitment to delivering healthcare services to its clients.

ClearMedi Healthcare, a Delhi-NCR headquartered healthcare company, is a joint venture between Medipass, a subsidiary of La Repubblica Group in Italy, KOS S.p.A. in Italy, and Clearview Healthcare India.

Established in 2010 by Shashi Kant Baliyan, ClearMedi Healthcare manages complex clinical services, including oncology, nuclear medicine, and radiology. It operates standalone super specialty hospitals with over 350 beds across different locations. 

ClearMedi's facilities span eight states and a union territory and have established themselves as trusted leaders in the healthcare sector, particularly in providing cancer care services.